Sjögren Antibodies

Dry eyes that eye drops barely touch. A mouth so dry you wake up at night for water. Joint aches that come and go without explanation. These symptoms affect millions of people, and most chalk them up to aging, allergies, or stress. But in a meaningful number of cases, the real cause is an autoimmune process where the body's immune system has turned against its own moisture-producing glands. The way to find out is to measure two specific autoantibodies (immune proteins that mistakenly target your own tissues) in your blood.

This panel measures SS-A (also called anti-Ro) and SS-B (also called anti-La), two proteins your immune system makes when it mistakenly targets certain tissues in your body. Individually, each antibody tells part of the story. Together, they reveal not just whether autoimmune activity is present, but what kind of autoimmune pattern you have, how aggressive it may be, and which conditions are most likely driving your symptoms.

What This Panel Reveals

SS-A and SS-B antibodies target proteins found inside your cells, particularly in the salivary glands, tear glands, and other tissues. When your immune system produces these antibodies, it typically causes inflammation that slowly damages those glands, reducing their ability to produce moisture. This is the hallmark of Sjogren's syndrome, an autoimmune condition that affects roughly 0.5% to 1% of the general population, with a strong female predominance of about 9 to 1.

But the clinical picture extends well beyond dry eyes and mouth. SS-A antibodies appear in several autoimmune conditions, including systemic lupus erythematosus (lupus), rheumatoid arthritis, and mixed connective tissue disease. SS-B antibodies are more specific to Sjogren's syndrome. The combination of both results tells you something neither can tell you alone: how likely you are to have primary Sjogren's versus another autoimmune condition, and what your risk profile looks like for complications in other organs.

Why Both Antibodies Matter More Than Either Alone

SS-A is the more sensitive marker. It is found in roughly 60% to 75% of people with primary Sjogren's syndrome and in 25% to 40% of people with lupus. But SS-A alone cannot distinguish between these conditions. SS-B, on the other hand, is found in only about 25% to 40% of people with Sjogren's syndrome and is rare in lupus without concurrent Sjogren's. SS-B is almost never found without SS-A also being present.

This asymmetry is the key to reading the panel as a unit. When both antibodies are positive, the pattern points strongly toward primary Sjogren's syndrome. When SS-A is positive but SS-B is negative, the picture is broader: it could indicate Sjogren's, lupus, or another connective tissue disease, and further evaluation is warranted. A negative result on both antibodies does not fully rule out Sjogren's (some people with the disease are seronegative, meaning they test negative for these antibodies), but it makes autoimmune-driven dryness much less likely.

How to Read Your Results Together

The interpretation of this panel depends entirely on the pattern of results, not on either test in isolation. Here are the patterns that matter most.

The 2016 ACR/EULAR classification criteria for primary Sjogren's syndrome assign a score of 3 (out of a threshold of 4) to a positive SS-A result alone. A positive salivary gland biopsy also scores 3, making these two items equally weighted as the most important criteria in the diagnostic framework. Either one, combined with any single additional criterion, meets the classification threshold.

Implications Beyond Sjogren's

SS-A antibodies carry specific clinical significance for women of childbearing age. Mothers with SS-A antibodies face a roughly 2% risk of congenital heart block in the developing fetus, a serious condition where antibodies crossing the placenta damage the baby's heart tissue. Neonatal lupus, which typically causes a temporary skin rash, occurs in a somewhat larger percentage of exposed infants. These risks are concentrated between weeks 16 and 24 of pregnancy. If you are SS-A positive and planning a pregnancy, fetal heart monitoring during this window is standard practice.

SS-A positivity is also associated with a higher risk of disease that extends beyond the glands, including interstitial lung disease (scarring of lung tissue), kidney inflammation, inflammation of small blood vessels in the skin, and peripheral neuropathy (nerve damage causing numbness or tingling in the hands and feet). People who are SS-A positive tend to have more widespread disease compared to those who are seronegative. In lupus, SS-A positivity is associated with unusual sensitivity to sunlight and a specific type of sun-sensitive skin rash called subacute cutaneous lupus, along with lower rates of kidney involvement.

When Results Can Be Misleading

A few situations can complicate interpretation. SS-A antibodies are found in about 0.5% to 3% of the healthy general population, meaning a positive result in someone without symptoms does not automatically mean disease is present or inevitable. However, studies tracking healthy SS-A positive individuals have shown that a portion go on to develop autoimmune symptoms over time, making the result worth monitoring.

Some laboratories report SS-A as two subtypes: Ro52 and Ro60. Ro60 is the form most closely tied to Sjogren's syndrome and lupus, while Ro52 can appear in a wider range of inflammatory conditions, including myositis (muscle inflammation) and interstitial lung disease. If your lab reports subtypes, the clinical picture may differ depending on which form is detected.

Tracking Over Time

Once established, SS-A and SS-B antibody levels tend to remain stable over years. They do not fluctuate the way some other autoimmune markers do. This means the primary value of initial testing is in diagnosis, not in monitoring disease flares. However, repeating the panel has specific uses.

If your initial results were negative but your symptoms persist or worsen, retesting in 6 to 12 months is reasonable because antibodies can appear over time as autoimmune processes evolve. If you were previously positive, serial testing can track whether antibody levels are rising, which in some studies has correlated with progression from mild glandular disease to more widespread involvement. For women planning pregnancy, confirming SS-A status before conception helps guide fetal monitoring decisions.

What to Do with Your Results

If both antibodies are positive, a rheumatologist should evaluate you for Sjogren's syndrome and assess for systemic involvement, including lung, kidney, and nervous system checks. If only SS-A is positive, broader autoimmune evaluation is warranted because the range of possible conditions is wider.

If both are negative but you have persistent dryness, fatigue, or joint pain, the results are still useful. They shift the focus away from antibody-mediated autoimmune disease and toward other explanations, including seronegative Sjogren's (a form where these antibodies are absent, which requires lip biopsy to confirm), medication side effects, hormonal changes, or other conditions. A negative result is not wasted; it narrows the field.

For anyone with a positive result, consider adding a complete blood count (CBC), a metabolic panel, and complement levels (C3 and C4) to screen for organ involvement. An ANA test and anti-dsDNA antibody help determine whether lupus is part of the picture. Monitoring for lymphoma (a cancer of the immune system) is also appropriate in confirmed Sjogren's, as people with this condition carry roughly a 5% to 10% lifetime risk of developing non-Hodgkin lymphoma, a rate approximately 15 to 20 times higher than the general population.